A significant proportion of patients with colon cancer who undergo curative surgical resection develop metastatic disease. Over the last 20 years large prospective randomised studies have demonstrated a clear survival benefit for patients with stage III colon cancer who are treated with adjuvant 5FU based chemotherapy. At the present time 6 months of 5FU and leucovorin is generally considered the standard adjuvant therapy. For stage II disease the routine use of adjuvant treatment remains controversial. Newer drugs such as oxaliplatin, irinotecan, and the oral fluoropyrimidines have proven active in advanced colorectal cancer and are currently being evaluated in the adjuvant setting. Molecular markers for this disease are being identified and may help define those patients who would benefit from therapy. The integration of adjuvant immunotherapy with conventional chemotherapy offers the potential to improve the long-term outcome for surgically resected colon cancer.
ParkinDMBrayFFerlayJPisaniPEstimating the world cancer burden: Globocan 2000. Int J Cancer2001; 94: 153–156.
2.
ParkinDMPisaniPFerlayJGlobal cancer statistics. CA Cancer J Clin1999; 49: 33–64, 1.
3.
BuyseMZeleniuch-JacquotteAChalmersTCAdjuvant therapy of colorectal cancer. Why we still don't know. JAMA1988; 259: 3571–8.
4.
WolmarkNFisherBRocketteHRedmondCWickerhamDLFisherERJonesJGlassALernerHLawrenceW: Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst1988;80:30–36.
5.
LaurieJAMoertelCGFlemingTRWieandHSLeighJERubinJMcCormackGWGerstnerJBKrookJEMalliardJ: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol1989; 7: 1447–1456.
6.
MoertelCGFlemingTRMacDonaldJSHallerDGLaurieJAGoodmanPJUngerleiderJSEmersonWATorneyDCGlickJH: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med1990;322:352–358.
7.
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA1990; 264: 1444–1450.
8.
MoertelCGFlemingTRMacDonaldJSHallerDGLaurieJATangenCMUngerleiderJSEmersonWATorneyDCGlickJH: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med1995; 122: 321–326.
9.
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol1992; 10: 896–903.
10.
WolmarkNRocketteHFisherBWickerhamDLRedmondCFisherERJonesJMamounasEPOreLPetrelliNJ: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol1993;11:1879–1887.
11.
O'ConnellMJMailliardJAKahnMJMacDonaldJSHallerDGMayerRJWieandHSControlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol1997;15:246–250.
12.
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer.International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet1995;345:939–944.
13.
HallerDGCatalanoPMacDonaldJSFluorouracil, leuco vorin and levamisole adjuvant therapy for colon cancer: Five year final report of INT-0089. Proceedings of the American Society of Clinical Oncology17, 256. 1998. (Abstract).
14.
O'ConnellMJLaurieJAKahnM: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol1998;16:295–300.
15.
WolmarkNRocketteHMamounasEJonesJWieandSWickerhamDLBearHDAtkinsJNDimitrovNVGlassAGFisherERFisherBClinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol1999;17:3553–3559.
16.
TaalBGVan TinterenHZoetmulderFAAdjuvant 5FU plus levamisole in colonic or rectal cancer: Improved survival in stage II and III. Br J Cancer2001;85:1437–1443.
17.
PorschenRBermannALofflerTHaackGRettigKAngerYStrohmeyerGFluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: Results of the trial adjCCA-01. J Clin Oncol2001;19:1787–1794.
18.
Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial. QUASAR Collaborative Group. Lancet2000; 355: 1588–1596.
19.
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer.International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol1999;17:1356–1363.
20.
MamounasEWieandSWolmarkNBearHDAtkinsJNSongKJonesJRocketteHComparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol1999;17:1349–1355.
21.
SchragDGelfandSBachPBAdjuvant Chemotherapy for Stage II Colon Cancer: Insight from a SEER-Medicare Cohort. Proceedings of the American Society of Clinical Oncology20, 123. 2001. (Abstract).
22.
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.Meta-analysis Group In Cancer. J Clin Oncol1998; 16:301–308.
23.
PoplinEBenedettiJEstesNPhase III Randomized Trial of Bolus 5-FU/Leucovorin/Levamisole versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High Risk Colon Cancer (SWOG 9415/INT-0153). Proceedings of the American Society of Clinical Oncology19, 240. 2000. (Abstract).
24.
SainiACunninghamDNormanAMulticentre Randomized Trial of Protracted Venous Infusion (PVI) 5 FU Compared to 5 FU/Folinic Acid (5FU/FA) as Adjuvant Therapy for Colorectal Cancer. Proceedings of the American Society of Clinical Oncology19, 240. 2000. (Abstract).
25.
AndreTColinPLouvetCPhase III trial (GERCOR C96.1) comparing bimonthly LV5FU2 to monthly 5FU-leucoverin high dose (LV hd) in patients with Dukes B2 and C colon cancer. Proceedings of the American Society of Clinical Oncology21, 133. 2002. (Abstract).
26.
DouillardJYCunninghamDRothADNavarroMJamesRDKarasekPJandikPIvesonTCarmichaelJAlaklMGruiaGAwadLRougierPIrinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet2000;355:1041–1047.
27.
RothenbergMLMeropolNJPoplinEAVan CutsemEWadlerSMortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol2001;19:3801–7380.
28.
GiacchettiSPerpointBZidaniRLe BailNFaggiuoloRFocanCCholletPLloryJFLetourneauYCoudertBBertheaut-CvitkovicFLarregain-FournierDLe RolAWalterSAdamRMissetJLLeviFPhase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol2000;18:136–147.
29.
GoldbergRMMortonRFSargentDJN9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proceedings of the American Society of Clinical Oncology21, 128. 2002. (Abstract).
30.
HoffPMAnsariRBatistGCoxJKochaWKupermincMMarounJWaldeDWeaverCHarrisonEBurgerHUOsterwalderBWongAOWongRComparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as *firstline treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol2001;19:2282–2292.
31.
Van CutsemETwelvesCCassidyAllman DBajettaEBoyerMBugatRFindlayMFringsSJahnMMcKendrickJOsterwalderBPerez-MangaGRossoRRougierPSchmiegelWHSeitzJFThompsonPVieitezJMWeitzelCHarperP; Zeloxa Colorectal Cancer Study Group: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol2001;19:4097–4106.
32.
PazdurRDouillardJYSkillingsJRMulticenter Phase III Study of 5-Fluorouracil (5-FU) or UFT[Superscript TM] in Combination with Leucovorin (LV) in Patients with Metastatic Colorectal Cancer. Proceedings of the American Society of Clinical Oncology18, 263. 1999. (Abstract).
33.
RiethmullerGHolzESchlimok: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol1998;16:1788–1794.
34.
PuntCNagyADouillardJYFigerASkovsgaardTMonJBaroneCFountzilasGRiessHMoylanEJonesDDethlingJColmanJCowardLMacGregor SEdrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: A randomised study. Lancet2002;360:671–677.
35.
FieldsALAKellerAMSchwartzbergLEdrecolomab (17–1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: Results of a randomised north american phase III study. Proceedings of the American Society of Clinical Oncology21, 128. 2002. (Abstract).
36.
ElsalehHJosephDGrieuFZepsNSpryNIacopettaBAssociation of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet2000; 355: 1745–1750.
37.
RibicCSargentDJMooreMTumour microsatellite instability (MSI) and the benefit of 5FU based chenmotherapy in stage II and III colon cancer: A pooled molecular reanalysis of randomised chemotherapy trials. Proceedings of the American Society of Clinical Oncology.2002. (Abstract).
38.
KimGPColangeloLAllegraCPrognostic role of microsatellite instability in colon cancer. Proceedings of the American Society of Clinical Oncology.2001. (Abstract).
39.
MeterissianSHKontogianneaMAl SowaidiMLinjawiAHalwaniFJamisonBEdwardesMBcl-2 is a useful prognostic marker in Dukes' B colon cancer. Ann Surg Oncol2001; 8:533–537.
